Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

Sector Expert: Vernon Bernardino

Seaport Global Securities

Image: Vernon Bernardino

Vernon Bernardino is an analyst in Seaport Global Securities' life sciences equity research department. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and immunotherapy companies that focus on treatment of cancer, infectious diseases and cell-based therapies targeting inflammatory disorders and vascular diseases. Bernardino brings more than 10 years of experience covering life sciences companies at various financial institutions, including FBR & Co., Rodman & Renshaw, UBS and Dawson James. Earlier in his career, Bernardino was a buyside analyst at Nicholas Applegate Capital Management, and founded the strategic advisory group Oceros Advisors LP. Bernardino holds a bachelor's degree from Rutgers University and a master's degree in business administration (finance) from the University of San Diego.

Recent Interviews

The Inflammatory Disease Marketplace Meets the Drug Pricing Controversy: FBR & Co.'s Vernon Bernardino (10/21/15)

Chronic inflammation causes long-term pain and tissue scarring, manifesting in a range of diseases from rheumatoid arthritis to liver cirrhosis. With the introduction of gene therapy and immunotherapeutics, novel strategies targeting inflammatory disorders are being developed, creating hope for patients with no other clinical options. In this interview with The Life Sciences Report, FBR & Co.'s Vernon Bernardino provides insight on companies developing such strategies that also present solid investment opportunities.

Biotechs with Upside Possibilities Target Ebola and Liver Disease: MLV & Co.'s Vernon Bernardino (9/10/14)

Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.

Not All Stem Cells Are Created Equal: Vernon Bernardino (10/3/13)

Biotech companies are fiercely competing to create the newest and best miracle drugs using stem cell technologies. How can an investor spot the potentially victorious outliers amid the chaos of rival scientific claims? The failure rate of new product development in the only recently understood cell space is terrifying, but in this interview with The Life Sciences Report, analyst Vernon Bernardino of MLV & Co. reveals his formula for evaluating the strongest contenders. Bernardino also names five companies with products that may succeed in this new and competitive space.

Recent Quotes

"ATNM was granted SME status, which provides assistance and financial support, as well as compelling commercial opportunities in the EU."

— Vernon Bernardino, FBR & Co. (8/9/16)
more >

"ATNM's focus on antibodies linked to radioactive payloads is underappreciated."

— Vernon Bernardino, FBR & Co. (6/29/16)
more >

"IMNP's b-mab could provide significant advantages over standard treatment for bullous pemphigoid."

— Vernon Bernardino, FBR & Co. (6/14/16)
more >

"IMNP's bertilimumab could play an important role in challenging inflammatory diseases."

— Vernon Bernardino, FBR & Co. (6/8/16)
more >

"IMNP is making meaningful progress advancing its portfolio of immuno-inflammation and immuno-oncology product candidates."

— Vernon Bernardino, FBR & Co. (5/20/16)
more >

"Based on encouraging preclinical datar, we think RNN's Supinoxin could become validated as a treatment for solid tumors."

— Vernon Bernardino, FBR & Co. (5/10/16)
more >

"We expect momentum for ATNM's Iomab-B to accelerate in mid-2016."

— Vernon Bernardino, FBR & Co. (4/29/16)
more >

"Securing funds from institutional investors is a strong vote of confidence in IMNP's ability to achieve near-term catalysts."

— Vernon Bernardino, MLV & Co (4/8/16)
more >

Due to permission requirements, not all quotes are shown.